An advanced AI system has solved a decade-old theoretical physics puzzle, proposing a new formula for gluon interactions. The AI, GPT-5.2 Pro, spent 12 hours developing a mathematical proof, revealing ...
India, Feb. 14 -- A team of physicists from leading institutions has collaborated with OpenAI's GPT-5.2 model to achieve a new result in theoretical physics, the AI company announced.
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...
Those that solve artificially simplified problems where quantum advantage is meaningless. Those that provide no genuine quantum advantage when all costs are properly accounted for. This critique is ...
Oracle-based quantum algorithms cannot use deep loops because quantum states exist only as mathematical amplitudes in Hilbert space with no physical substrate. Criticall ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results